Clive Dix appointed chairman of Crescendo Biologics

pharmafile | January 21, 2010 | Appointment | Research and Development |  Crescendo Biologics, appointment, research and development 

Cambridge, UK-based Crescendo Biologics has appointed Clive Dix as chairman.

He will work closely with chief scientific officer Mike Romanos to drive the development of the company and its proprietary antibody fragment technologies following the recent £4.5 million seed round fundraising.

Dr Dix has a track record that spans more than 20 years in the pharmaceutical and biotech industries.

He is the chairman of the BioIndustry Association, the trade association for innovative enterprises in the UK’s bioscience sector, and was previously co-founder and chief executive of PowderMed, the vaccines development company acquired by Pfizer in November 2006.

Prior to running PowderMed, Dr Dix was senior vice president, research and development and a board member of PowderJect Pharmaceuticals until its acquisition by Chiron Vaccines in 2003.

He began his career in industry at Ciba-Geigy before moving to GlaxoWellcome, which he left as UK research director in 2001.

Dr Dix is currently also non-executive chairman of Modern Biosciences and Auralis.